Both rosiglitazone and pioglitazone are safe and well tolerated for the treatment of diabetes type 2.
However, researchers at the University of Texas Diabetes Institute in San Antonio, Texas, United States, caution that because diabetic patients are at risk for coronary artery disease, doctors should consider the effects of each agent on lipid levels when choosing a specific thiazolidinedione.
Twenty patients with diabetes type 2, were treated with both therapeutic agents for a period of three months. The patients had been treated with rosiglitazone at 4 mg twice a day for three months or longer, and then switched to pioglitazone 45 mg once daily for the same period. Glycaemic control proved excellent, and was essentially equivalent throughout the use of two therapies, according to researchers.
The mean Hb A1c level was 7.6 percent at baseline. This dropped to 6.6 percent with rosiglitazone, and 6.3 percent with pioglitazone. However, the researchers found differences in lipid levels between the two therapies. During treatment with rosiglitazone the triglyceride levels rose 13 percent, but with pioglitazone it fell below the baseline levels with an overall reduction of 24 percent.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!